We are a leading healthcare campus encompassing all fields of health: from healthcare and research to teaching and management.
Professionalism, commitment and research by professionals on the Campus are the key elements in offering patients excellent care.
We are committed to research as a tool to provide solutions to the daily challenges we face in the field of medical healthcare.
Thanks to our healthcare, teaching and research potential, we work to incorporate new knowledge to generate value for patients, professionals and the organization itself.
We generate, transform and transmit knowledge in all areas of the health sciences, helping to train the professionals of the future.
We are defined by our vocation for communication. We invite you to share everything that happens at Vall d'Hebron Barcelona Hospital Campus, and our doors are always open.
Hospital donations
Research donations
Dr. Rubén Hernández Alcoceba, Division of Gene Therapy and Hepatology CIMA -Universidad de Navarra (UNAV)
"Adenoviral vectors"
The Adenoviridae family comprises a wide variety of human and animal viruses sharing genetic and structural characteristics. Their 80-100 nm non-enveloped icosahedral capsids contain core proteins and a ~36 Kb double-stranded genome packed with structural and regulatory genes. The study of adenoviral life cycle and its interactions with the host has revealed fundamental biological processes over several decades, and most likely it will enlighten us for many years to come. More recently, adenoviruses have become versatile platforms for the development of therapeutic agents. The stability of their genome and the relative simplicity of its manipulation have enabled the development of a wide repertoire of adenovirus-based products with different properties, all of them sharing a high transduction efficacy in mammalian cell cultures and in vivo. Their lytic life cycle has been exploited for the development of oncolytic agents, whereas progressive deletions of the viral genomes has resulted in gene therapy vectors with optimal cloning capacity and increased episomal stability. The strong immune responses elicited by adenoviral particles have been a drawback for early generation adenoviral vectors, but they are currently harnessed to develop vaccines and improved cancer immunotherapies.This seminar will cover general characteristics of adenovirus and their adaptation as gene therapy vectors, with special attention to High-Capacity Adenoviral vectors.
Host: Immunomediated Diseases and Innovative Therapies jordi.barquinero@vhir.org
The acceptance of these terms implies that you give your consent to the processing of your personal data for the provision of the services you request through this portal and, if applicable, to carry out the necessary procedures with the administrations or public entities involved in the processing. You may exercise the mentioned rights by writing to web@vallhebron.cat, clearly indicating in the subject line “Exercise of LOPD rights”. Responsible entity: Vall d’Hebron University Hospital (Catalan Institute of Health). Purpose: Subscription to the Vall d’Hebron Barcelona Hospital Campus newsletter, where you will receive news, activities, and relevant information. Legal basis: Consent of the data subject. Data sharing: If applicable, with VHIR. No other data transfers are foreseen. No international transfer of personal data is foreseen. Rights: Access, rectification, deletion, and data portability, as well as restriction and objection to its processing. The user may revoke their consent at any time. Source: The data subject. Additional information: Additional information can be found at https://hospital.vallhebron.com/es/politica-de-proteccion-de-datos.